JOINN Biologics Secures $150 Million Funding to Revolutionize Biotech and Biopharmaceuticals Manufacturing

We are excited to announce that JOINN Biologics, a leader in biotech contract development and manufacturing services based in the California Bay Area, has successfully raised $150 million in funding.

This significant infusion of capital will empower us to enhance our capabilities and accelerate growth as we continue to provide comprehensive CDMO services for biologics and advanced therapies.

With over 20 years of experience supporting drug discovery and development, JOINN Biologics is dedicated to enriching the biotech and biopharmaceutical landscape, from molecular assessment and clinical trial material production to commercial-scale cGMP manufacturing and analytical development.

The funding will be strategically allocated toward expanding our production facilities, advancing our technologies, and bolstering our talent pool, enabling us to further optimize our services and meet the increasing demands within the industry.

As we strengthen our commitment to innovation and high-quality bio-manufacturing, this investment will play a crucial role in our overarching mission: delivering unparalleled support to our global clients and partners.

We firmly believe that by enhancing our operational capabilities and maintaining our focus on patient needs, we can drive significant advancements in healthcare outcomes.

In these challenging times, JOINN Biologics remains steadfast in its mission to foster a safer and healthier community while continuing to thrive in a rapidly evolving market.

We are incredibly grateful to our investors for their confidence in our vision and are eager to share the next chapter of our journey towards revolutionizing biopharmaceutical manufacturing.

For more details about our services and partnerships, visit us at JOINN Biologics.